Valuation: HighTide Therapeutics, Inc.

Market Cap 1.51B 1.77B 225M 200M 186M 169M 319M 21.38B 324M 2.23B 875M 11.16B 846M 828M 35.57B P/E 2024
-1.41x
P/E 2025 -5.19x
Enterprise Value 1.13B 1.33B 169M 150M 139M 127M 239M 16.05B 243M 1.67B 657M 8.38B 635M 621M 26.7B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
63.21%
Yield 2024 *
-
Yield 2025 -
1 day+3.17%
1 week-9.64%
Current month-9.90%
1 month-2.83%
3 months+12.55%
6 months-15.21%
Current year+4.92%
1 week 3
Extreme 3
3.38
1 month 3
Extreme 3
3.66
Current year 1.8
Extreme 1.8
4.72
1 year 1.8
Extreme 1.8
4.72
3 years 0.72
Extreme 0.72
13.18
5 years 0.72
Extreme 0.72
13.18
10 years 0.72
Extreme 0.72
13.18
Manager TitleAgeSince
Chief Executive Officer 56 31/12/2010
Director of Finance/CFO 57 30/11/2022
Chief Tech/Sci/R&D Officer - 01/02/2026
Director TitleAgeSince
Chairman 56 -
Director/Board Member 44 14/05/2023
Director/Board Member 68 29/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
30/04/26 Other

Director

1,800,000 0.3151%
01/04/26 Other

Chief Executive Officer

8,325,618 1.4572%
01/04/25 Other

Chief Executive Officer

3,960,550 0.7694%
Change 5-day change 1-year change 3-year change Capi.($)
+3.17%-9.64%-6.21% - 218M
-6.60%-8.56%+42.79%+64.16% 68.98B
-4.09%-0.11%+2.31%+54.81% 53.15B
+0.03%+5.56%+10.18%+41.75% 50.83B
-1.53%+2.70%+29.72%+34.13% 44.61B
-5.97%-6.22%+258.21%+421.57% 40.57B
-1.34%+4.12%+16.05%+112.18% 42.53B
+6.53%+8.02%+15.74%+53.94% 30.95B
-0.90%-10.49%+31.48%-1.63% 25.44B
-2.76%-9.54%-16.53%-9.55% 22.66B
Average -1.35%-1.42%+38.37%+85.71% 37.99B
Weighted average by Cap. -2.42%-0.10%+44.71%+90.25%

Financials

2024 2025
Net sales - -
Net income -382M -448M -57.06M -50.72M -47.01M -42.77M -80.71M -5.42B -82M -565M -222M -2.83B -214M -210M -9.01B -245M -287M -36.61M -32.54M -30.16M -27.44M -51.79M -3.47B -52.62M -363M -142M -1.81B -137M -134M -5.78B
Net Debt -413M -484M -61.69M -54.84M -50.83M -46.24M -87.26M -5.86B -88.66M -611M -240M -3.06B -232M -227M -9.74B -376M -441M -56.19M -49.95M -46.29M -42.12M -79.48M -5.33B -80.75M -556M -218M -2.78B -211M -206M -8.87B
Projected Income Statement - Annual - HighTide Therapeutics, Inc.
Logo HighTide Therapeutics, Inc.
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The Company has developed a product pipeline of multiple product candidates in-house, covering many indications in metabolic and digestive diseases among which, some are at clinical-stage. The Company’s core product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases. The Company conducts operations in the United States, Mainland China, Hong Kong and Australia.
Employees
55
Date Price Change Volume
16/10/26 HK$3.095 +3.17% 178,500
15/10/26 HK$3.000 -2.91% 68,000
14/10/26 HK$3.090 -0.96% 220,500
13/10/26 HK$3.120 -2.35% 631,000
12/10/26 HK$3.195 -6.72% 325,500

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - HighTide Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. 2511 Stock